Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor

Ravi K. Anchoori, Vidyasagar Anchoori, Brandon Lam, Ssu Hsueh Tseng, Samarjit Das, Fernanda Carrizo Velasquez, Balasubramanyam Karanam, Deepika Poddatoori, Ramesh Patnam, Michelle A. Rudek, Yung Nien Chang, Richard B.S. Roden

Research output: Contribution to journalArticlepeer-review

Abstract

Bortezomib has been successful for treatment of multiple myeloma, but not against solid tumors, and toxicities of neuropathy, thrombocytopenia and the emergence of resistance have triggered efforts to find alternative proteasome inhibitors. Bis-benzylidine piperidones such as RA190 covalently bind ADRM1/RPN13, a ubiquitin receptor that supports recognition of polyubiquitinated substrates of the proteasome and their subsequent deububiqutination and degradation. While these candidate RPN13 inhibitors (iRPN13) show promising anticancer activity in mouse models of cancer, they have suboptimal drug-like properties. Here we describe Up284, a novel candidate iRPN13 possessing a central spiro-carbon ring in place of RA190's problematic piperidone core. Cell lines derived from diverse cancer types (ovarian, triple negative breast, colon, cervical and prostate cancers, multiple myeloma and glioblastoma) were sensitive to Up284, including several lines resistant to bortezomib or cisplatin. Up284 and cisplatin showed synergistic cytotoxicity in vitro. Up284-induced cytotoxicity was associated with mitochondrial dysfunction, elevated levels of reactive oxygen species, accumulation of very high molecular weight polyubiquitinated protein aggregates, an unfolded protein response and the early onset of apoptosis. Up284 and RA190, but not bortezomib, enhanced antigen presentation in vitro. Up284 cleared from plasma in a few hours and accumulated in major organs by 24 h. A single dose of Up284, when administered to mice intra peritoneally or orally, inhibited proteasome function in both muscle and tumor for >48 h. Up284 was well tolerated by mice in repeat dose studies. Up284 demonstrated therapeutic activity in xenograft, syngeneic and genetically-engineered murine models of ovarian cancer.

Original languageEnglish (US)
Article numbere0285221
JournalPloS one
Volume18
Issue number6 June
DOIs
StatePublished - Jun 2023

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor'. Together they form a unique fingerprint.

Cite this